IDEXX Laboratories, Inc. is a member of the S&P 500® Index and is a leader in pet healthcare innovation, offering diagnostic and software products and services that deliver solutions and insights to practicing veterinarians around the world. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for livestock and poultry and tests for the quality and safety of water and milk and point-of-care and laboratory diagnostics for human medicine. Headquartered in Maine, IDEXX employs more than 9,000 people and offers products to customers in over 175 countries.

Company profile
Ticker
IDXX
Exchange
Website
CEO
Jonathan Jay Mazelsky
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
342 Saco Street, LLC • Beijing IDEXX Laboratories Co. Limited • ezyVet US, Inc. • IDEXX Animana B.V. • IDEXX Brasil Laboratórios Ltda. • IDEXX Brasil Participações Ltda. • IDEXX Diagnostic Limited • IDEXX Diavet AG • IDEXX Distribution, Inc. • IDEXX GmbH ...
IRS number
10393723
IDXX stock data
Analyst ratings and price targets
Latest filings (excl ownership)
SD
Conflict minerals disclosure
31 May 23
8-K
Submission of Matters to a Vote of Security Holders
19 May 23
10-Q
2023 Q1
Quarterly report
2 May 23
8-K
Results of Operations and Financial Condition
2 May 23
ARS
2022 FY
Annual report to shareholders
31 Mar 23
DEFA14A
Additional proxy soliciting materials
31 Mar 23
DEF 14A
Definitive proxy
31 Mar 23
10-K
2022 FY
Annual report
16 Feb 23
8-K
IDEXX Laboratories Announces Fourth Quarter and Full Year 2022 Results
6 Feb 23
10-Q
2022 Q3
Quarterly report
1 Nov 22
Transcripts
IDXX
Earnings call transcript
2023 Q1
2 May 23
IDXX
Earnings call transcript
2022 Q4
6 Feb 23
IDXX
Earnings call transcript
2022 Q3
1 Nov 22
IDXX
Earnings call transcript
2022 Q2
2 Aug 22
IDXX
Earnings call transcript
2022 Q1
4 May 22
IDXX
Earnings call transcript
2021 Q4
2 Feb 22
IDXX
Earnings call transcript
2021 Q3
2 Nov 21
IDXX
Earnings call transcript
2021 Q2
30 Jul 21
IDXX
Earnings call transcript
2021 Q1
4 May 21
IDXX
Earnings call transcript
2020 Q4
2 Feb 21
Latest ownership filings
4
JONATHAN W AYERS
22 May 23
4
JONATHAN JAY MAZELSKY
19 May 23
4
Sophie V. Vandebroek
19 May 23
4
M ANNE SZOSTAK
19 May 23
4
SAM SAMAD
19 May 23
4
Lawrence D Kingsley
19 May 23
4
DANIEL M JUNIUS
19 May 23
144
Notice of proposed sale of securities
19 May 23
4
STUART ESSIG
19 May 23
4
Asha COLLINS
19 May 23
Financial summary
Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 111.37 mm | 111.37 mm | 111.37 mm | 111.37 mm | 111.37 mm | 111.37 mm |
Cash burn (monthly) | 393.00 k | 7.77 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 812.76 k | 16.07 mm | n/a | n/a | n/a | n/a |
Cash remaining | 110.55 mm | 95.30 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | 281.3 | 12.3 | n/a | n/a | n/a | n/a |
Institutional ownership, Q1 2023
85.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1007 |
Opened positions | 133 |
Closed positions | 88 |
Increased positions | 319 |
Reduced positions | 388 |
13F shares | Current |
---|---|
Total value | 35.19 tn |
Total shares | 70.67 mm |
Total puts | 319.60 k |
Total calls | 273.58 k |
Total put/call ratio | 1.2 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 8.70 mm | $4.35 tn |
Vanguard | 8.20 mm | $4.10 tn |
STT State Street | 3.67 mm | $1.84 tn |
Alliancebernstein | 3.38 mm | $1.69 tn |
Fundsmith | 2.95 mm | $1.48 tn |
Bamco | 2.36 mm | $1.18 tn |
Geode Capital Management | 1.95 mm | $971.57 bn |
BEN Franklin Resources | 1.35 mm | $677.08 bn |
Blair William & Co | 1.21 mm | $604.69 bn |
IVZ Invesco | 1.19 mm | $594.51 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 May 23 | Ayers Jonathan W | Common Stock | Sell | Dispose S | No | No | 498.48 | 300 | 149.54 k | 137,039 |
19 May 23 | Ayers Jonathan W | Common Stock | Sell | Dispose S | No | No | 497.6556 | 759 | 377.72 k | 137,339 |
19 May 23 | Ayers Jonathan W | Common Stock | Sell | Dispose S | No | No | 495.9351 | 886 | 439.40 k | 138,098 |
19 May 23 | Ayers Jonathan W | Common Stock | Sell | Dispose S | No | No | 494.276 | 1,229 | 607.47 k | 138,984 |
19 May 23 | Ayers Jonathan W | Common Stock | Sell | Dispose S | No | No | 492.8167 | 1,426 | 702.76 k | 140,213 |
19 May 23 | Ayers Jonathan W | Common Stock | Sell | Dispose S | No | No | 491.59 | 400 | 196.64 k | 141,639 |
19 May 23 | Ayers Jonathan W | Common Stock | Sell | Dispose S | No | No | 490.0283 | 300 | 147.01 k | 142,039 |
19 May 23 | Ayers Jonathan W | Common Stock | Sell | Dispose S | No | No | 488.7748 | 1,308 | 639.32 k | 142,339 |
19 May 23 | Ayers Jonathan W | Common Stock | Sell | Dispose S | No | No | 487.8169 | 2,254 | 1.10 mm | 143,647 |
19 May 23 | Ayers Jonathan W | Common Stock | Sell | Dispose S | No | No | 486.9211 | 1,138 | 554.12 k | 145,901 |
News
Here's How Much You Would Have Made Owning IDEXX Laboratories Stock In The Last 15 Years
22 May 23
IDEXX Laboratories' Debt Overview
16 May 23
$1000 Invested In This Stock 20 Years Ago Would Be Worth $13,000 Today
4 May 23
Expert Ratings for IDEXX Laboratories
3 May 23
Atlantic Equities Reiterates Overweight on IDEXX Laboratories, Maintains $600 Price Target
3 May 23